Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD by Miller, Gerald et al.
Nephrol Dial Transplant (2012) 27: 2198–2205
doi: 10.1093/ndt/gfr589
Advance Access publication 29 October 2011
Cinacalcet HCl prevents development of parathyroid gland hyperplasia
and reverses established parathyroid gland hyperplasia in a rodent
model of CKD
Gerald Miller, James Davis, Edward Shatzen, Matthew Colloton, David Martin and Charles M. Henley
Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA
Correspondence and offprint requests to: Charles M. Henley; E-mail: chenley@amgen.com
Abstract
Background. Secondary hyperparathyroidism (sHPT) rep-
resents an adaptive response to progressively impaired con-
trol of calcium, phosphorus and vitamin D in chronic
kidney disease (CKD). It is characterized by parathyroid
hyperplasia and excessive synthesis and secretion of para-
thyroid hormone (PTH). Parathyroid hyperplasia in uremic
rats can be prevented by calcium-sensing receptor (CaSR)
activation with the calcimimetic cinacalcet (Sensipar /
Mimpara ); however, it is unknown, how long the effects
of cinacalcet persist after withdrawal of treatment or if
cinacalcet is efﬁcacious in uremic rats with established
sHPT.
Methods. We sought to determine the effect of cinacalcet
discontinuation in uremic rats and whether cinacalcet was
capable of inﬂuencing parathyroid hyperplasia in animals
with established sHPT.
Results. Discontinuation of cinacalcet resulted in reversal
of the beneﬁcial effects on serum PTH and parathyroid
hyperplasia. In rats with established sHPT, cinacalcet de-
creased serum PTH and mediated regression of parathyroid
hyperplasia. The cinacalcet-mediated decrease in parathy-
roid gland size was accompanied by increased expression
of the cyclin-dependent kinase inhibitor p21. Prevention of
cellular proliferation with cinacalcet occurred despite in-
creased serum phosphorus and decreased serum calcium.
Conclusions.The animal data provided suggest established
parathyroid hyperplasia can be reversed by modulating
CaSR activity with cinacalcet and that continued treatment
may be necessary to maintain reductions in PTH.
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Introduction
Disturbances in mineral metabolism that are secondary
to chronic kidney disease (CKD), such as hypocal-
cemia, hyperphosphatemia and impaired synthesis of
1,25-dihydroxyvitamin D3 (calcitriol), result in excess
parathyroid hormone (PTH) secretion that is a character-
istic of secondary hyperparathyroidism (sHPT) [1, 2]. In
contrast to low levels of parathyroid gland proliferation
and growth in normal adults, hyperparathyroidism secon-
dary to CKD is characterized by abnormally increased
parathyroid cell proliferation [3]. Increased parathyroid
cell proliferation has also been observed in patients with
primary hyperparathyroidism with demonstrable parathy-
roid hyperplasia [4]. Although molecular mechanisms
controlling parathyroid cell proliferation and gland size
are not yet clear, the endogenous cyclin-dependent kinase
(CDK) inhibitor p21, which inhibits progression from the
G1 to the S phase of the cell cycle [5, 6], may play a role in
decreasing parathyroid cell proliferation [7] and attenuating
parathyroid hyperplasia [8].
Parathyroid cell proliferation in uremic, as well as non-
uremic animals, is aggravated by hypocalcemia, phospho-
rous retention and vitamin D deﬁciency, underscoring the
importance of controlling these factors [9]. In addition, the
calcium-sensing receptor (CaSR), the vitamin D receptor
(VDR) and Klotho/ﬁbroblast growth factor (FGF) receptor
1 are downregulated, rendering the parathyroid gland more
resistant to serum calcium, calcitriol and FGF-23 further
exacerbating parathyroid hyperplasia [3, 10, 11]. Although
parathyroid cell proliferation is increased in mice with sys-
temic deletion of the VDR [12], parathyroid proliferation
was not signiﬁcantly altered when VDR site-speciﬁc dele-
tion was limited to the parathyroid gland [13]. Thus, effects
of vitamin D on parathyroid hyperplasia are mediated by
indirect mechanisms distinct from activation of parathyroid
VDR, such as the calcitropic effects of vitamin D. This is
further supported by the ability of calcium rescue diets to
correct sHPT in mice with systemic VDR deletion [14, 15].
Although FGF-23 can decrease PTH expression and FGF-
23 resistance develops with parathyroid hyperplasia, there
is no evidence of FGF-23 regulation of parathyroid gland
proliferation [10, 11, 16].
Serum calcium as sensed by the CaSR, a G protein-
coupled receptor located on the parathyroid gland, is a
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serum levels [17] and the CaSR is thought to play a key role
in parathyroid cell proliferation and hyperplasia [18].
Calcimimetics including R-568, AMG 641 [19] and cina-
calcet (Sensipar /Mimpara ) act as allosteric modulators
of the CaSR to increase sensitivity to endogenous calcium
[19–21], thereby shifting leftward the set point for calcium-
regulated PTH secretion [20, 22]. In dialysis patients with
sHPT, cinacalcet simultaneously lowers plasma PTH, se-
rum calcium and serum phosphorus [22]. Preclinical stud-
ies have shown that cinacalcet prevents parathyroid cell
proliferation and reduces gland weight in an animal model
of sHPT [5/6 nephrectomized rats (5/6 Nx)] [23], consistent
with studies using the calcimimetic R-568 [24, 25]. Clin-
ically, patients treated with cinacalcet have been shown to
exhibit reduced parathyroid glandular volume as visualized
by ultrasound [26] and regression of parathyroid gland
swelling [27]. Komaba and Fukagawa [28] subsequently
reported that cinacalcet effectively decreases serum PTH
and reduces parathyroid gland volume in patients with
moderate to severe sHPT [29]. While the precise mecha-
nism(s) of calcimimetic action on parathyroid gland size is
currently unknown, both preclinical and clinical ﬁndings
suggest that calcimimetic activation of CaSR is involved in
controlling the development of the excessive cell prolifer-
ation that occurs in parathyroid hyperplasia. Preliminary
ﬁndings suggest that calcimimetic-induced increases in
p21, an inhibitor of cell cycle progression, may be involved
in controlling parathyroid hyperplasia [1, 30].
The present report describes results from two separate
experiments with cinacalcet in 5/6 Nx uremic rats. The
purpose of the ﬁrst experiment was to evaluate reoccurr-
ence of sHPT (parathyroid gland hyperplasia and increased
PTH) after discontinuation of treatment. The purpose of the
second experiment was to evaluate the efﬁcacy of cinacal-
cet in rats with established CKD (e.g. using a therapeutic
paradigm whereby cinacalcet therapy was administered to
rats several weeks after induction of uremia). Expression of
p21 was evaluated to determine if calcimimetic-induced
changes in p21 correlated with parathyroid hyperplasia
during and after discontinuation of treatment.
Materials and methods
Animals and treatments
Experiments were performed under protocols approved by Amgen’s
Internal Animal Care and Use Committee. Male Sprague–Dawley rats
(300–350 g) purchased from Charles River Laboratories (Wilmington,
MA) were pair-housed with a 12/12-h light/dark cycle and provided stand-
ard rat chow and water ad libitum. A rodent model of CKD was induced
by 5/6 Nx, a two-step procedure reducing the original functional renal
mass by ﬁve-sixths, as previously described [23]. Sham-operated animals
underwent the same procedures without renal compromise.
Animals were randomized into treatment groups based on normal
distribution of body weights at baseline. Two separate experiments
were performed with cinacalcet (Figure 1): (i) to evaluate reoccurrence
of sHPT (parathyroid gland hyperplasia, increased PTH) after discon-
tinuation of treatment and (ii) to evaluate the therapeutic paradigm of
cinacalcet administration to rats with established CKD. Cinacalcet was
formulated in 20% Captisol:water (vehicle) at Amgen, Inc. (Thousand
Oaks, CA) to deliver 10 mg/kg (orally) in a l.5 mL/kg dose volume.
Based on exposure levels, the equivalent human dose to 10 mg/kg is 60
mg per subject, which is a standard clinical dose [31].
Experiment 1: cinacalcet prevention and control of sHPT (parathyroid
gland hyperplasia and increased PTH) and effects of discontinuation of
treatment in vivo
Animals were randomly placed into one of the following ﬁve groups
(n ¼ 8–10per group): 5/6 Nx administered (i) vehicle (20% Captisol:water
per day, orally) or (ii) cinacalcet (10 mg/kg) once per day for 6 weeks
(starting within 1 week after completion of the 5/6 Nx procedure) and then
sacriﬁced; (iii) 5/6 Nx administered cinacalcet for 6 weeks followed by
vehicle for 1–3 weeks and sacriﬁced, sham animals receiving either (iv)
vehicle or (v) cinacalcet for 9 weeks and then sacriﬁced (Figure 1A).
Blood samples were taken 4 h post-treatment at the times indicated for
determination of blood chemistries [PTH, blood urea nitrogen (BUN),
creatinine, phosphorus and total calcium]. Parathyroid weights, proliferat-
ing cell nuclear antigen (PCNA)- and p21-positive cells were determined
in tissue samples obtained at sacriﬁce. The data on p21 from three groups
(5/6 Nx vehicle 6 weeks, 5/6 Nx cinacalcet 6 weeks and 5/6 Nx cinacalcet
6 weeks followed by 3 weeks vehicle) were previously presented in sum-
mary form in a review article by Drueke et al. [1]. The data from these
animals are reported here to allow for interpretation of the complete
experiment.
Experiment 2: therapeutic administration of cinacalcet to rats with
established CKD
To determine the effectiveness of cinacalcet on reversing parathyroid hy-
perplasia in established sHPT, 5/6 Nx animals were subdivided into
groups in a separate study and all received vehicle for 6 weeks to allow
uremia, sHPT and parathyroid hyperplasia to progress (Figure 1B). In this
experimental therapeutic paradigm, uremic rats (6 weeks after 5/6 Nx)
were treated with cinacalcet (10 mg/kg/day, orally) or vehicle once daily
for 5 weeks and then sacriﬁced. Sham-operated rats treated with vehicle
for the entire time period (11 weeks) were used as controls. Animal
weights were monitored throughout the course of treatment to assess
any treatment-related weight changes. Blood was collected for determina-
tion of serum chemistry proﬁles at 2 days prior to surgery and 4 h post-
treatment at 6 and 11 weeks post-surgery.
Serum chemistry proﬁling
PTH levels were quantiﬁed according to the vendor’s instructions usingrat
PTH(1–34) immunoradiometric assay kits (Immutopics, San Clemente,
CA). BUN, total calcium, phosphorus and creatinine were measured using
a blood chemistry analyzer (AU 400; Olympus, Melville, NY).
Parathyroid histology
At sacriﬁce, dissected laryngo-tracheal complexes were stored 2–3 days in
zinc-buffered formalin, transferred to 70% alcohol and trimmed. For his-
tology, parathyroids were dissected from the thyroid, blotted dry and
weighed (Sartorius BP211D balance; Gottingen, Germany). After process-
ing and parafﬁn embedding, 5 lm sections were cut, placed onto charged
slides (VWR Scientiﬁc, West Chester, PA) and immunostained using a
Fig. 1. Experimental design. (A) Discontinuation. (B) Therapeutic
paradigm.
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or a mouse anti-rat p21 monoclonal antibody (Santa Cruz, CA) according
to vendors’ instructions. Parathyroid area from approximately the same
level of individual parathyroid was determined by visualizing tissue sam-
ples at 3100 on a Leitz Laborlux microscope (Wetzlar, Germany) and the
number of 0.01 mm
2 grids (calibrated area measurement graticle) over-
laying the central region of the parathyroid sections was counted by an
observer blinded to treatment groups. Total parathyroid area was calcu-
lated by multiplying the number of grids by 0.01 mm
2, after which the
number of PCNA-positive or p21-positive cells in the gridded sectional
area were counted and expressed as number of PCNA-positive cells/mm
2
and p21-positive cells/mm
2, respectively.
Statistics
Data are reported as mean   SEM unless otherwise indicated. Overall,
treatment effects were determined by analysis of variance (a ¼ 0.05).
Statistical signiﬁcance for comparisons between a given treatment group
with its corresponding vehicle control was determined by unpaired
Student’s t-test (a ¼ 0.05).
Results
Experiment 1: cinacalcet prevention and control of sHPT
(parathyroid gland hyperplasia and increased PTH) and
effects of discontinuation of treatment
Cinacalcet—prevention of elevated serum PTH and
parathyroid hyperplasia in uremic rats did not persist
after treatment withdrawal. Serum PTH levels were sig-
niﬁcantly higher in 5/6 Nx animals treated with vehicle for 6
weeks (258   29; n ¼ 1 0 )w h e nc o m p a r e dt os h a mc o n t r o l s
treated with vehicle for the same period (144   22 pg/mL;
n ¼ 10), consistent with the pathophysiology of sHPT in ro-
dents previously described [25]( Figure 1A). Cinacalcet
(10 mg/kg/day, orally) treatment for 6 weeks resulted in
a signiﬁcant (P < 0.05) reduction in serum PTH (53   12;
n¼ 9) compared to vehicle-treated 5/6 Nx animals (Figure 2).
The signiﬁcant reduction in PTH did not persist following
discontinuation of cinacalcet and within 1–3 weeks of treat-
ment termination, serum PTH increased to levels comparable
to those in vehicle-treated rats (Figure 2). This is in contrast to
the signiﬁcantly decreased PTH levels in 5/6 Nx rats treated
continuously with cinacalcet for 9 weeks (Figure 2). Serum
PTH was also signiﬁcantly lower in cinacalcet-treated sham
rats than in vehicle-treated sham animals (Figure 2).
Cinacalcet treatment of 5/6 Nx rats for 6 weeks resulted
in a signiﬁcant reduction of parathyroid hyperplasia, as
assessed by the number of PCNA-positive cells in the para-
thyroid glands (Figure 3) and by parathyroid weights
(Figure 4). Cinacalcet-treated 5/6 Nx rats had ~2-fold lower
number of PCNA-positive cells than vehicle-treated 5/6 Nx
rats, whose numbers were ~3-fold higher than vehicle-trea-
ted sham rats (Figure 3). Discontinuation of cinacalcet at
the end of a 6-week treatment resulted in gradual increases
in parathyroid hyperplasia [number of PCNA-positive
cells in the parathyroid (Figure 3) and parathyroid weights
(Figure 4)] over the next 3 weeks in contrast to the signiﬁ-
cantly decreased parathyroid hyperplasia in 5/6 Nx rats
treated continuously with cinacalcet for the entire 9-week
period (Figures 3 and 4). Cinacalcet treatment had no sig-
niﬁcant effect on the number of parathyroid PCNA-positive
cells (Figure 3) or parathyroid weight (Figure 4) in sham
animals compared to vehicle-treated sham animals.
Cinacalcet affects p21 expression the parathyroid glands
of uremic but not normal rats. As previously reported
[1], 6 weeks of cinacalcet administration to 5/6 Nx rats
Fig. 2. Cinacalcet-mediated reductions in PTH are reversed upon discon-
tinuation of treatment. 5/6 Nx and sham rats were treated with cinacalcet
(10 mg/kg/day) or vehicle for 6 weeks followed by up to 3 weeks of
vehicle in all groups. Values (mean 6 SEM; n ¼ 8–10 per group) shown
are from blood samples collected 4 h post-treatment at the end of 6, 7, 8 or
9 weeks after 5/6 Nx or sham surgery. Data represent mean 6 SEM
(*P < 0.05 as compared to 5/6 Nx, vehicle, sacriﬁce 6 week; #P < 0.05
as compared to 5/6 Nx, vehicle, sacriﬁce 9 week; ^P < 0.05 as compared
to respective sham, vehicle; n ¼ 8–10 per group).
Fig. 3. Parathyroidhyperplasiareturnsaftercessationofcinacalcettreatment.
Parathyroid hyperplasia was assessed by measuring PCNA-positive cells in
parathyroid glands from cinacalcet- or vehicle-treated rats at the end of 6 or 9
weeks of treatment and 1–3 weeks after termination of treatment. 5/6 Nx and
sham rats were treated with cinacalcet (10 mg/kg/day) or vehicle for 6 weeks
followedbyupto3weeksofvehicleinallgroups.Ratsweresacriﬁcedat6,7,8
or9weeks,andparathyroidsectionswerestainedforPCNAasamarkerofcell
proliferation.Datarepresentmean6SEM(*P<0.05ascomparedto5/6Nx,
vehicle,sacriﬁce6week;#P<0.05ascomparedto5/6Nxvehicle,sacriﬁce9
week. n ¼ 11–17 parathyroid gland sections stained for PCNA per group).
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persist at 3 weeks following discontinuation of treatment.
We expanded on these studies to determine the time course
for changes in p21 in uremic rats 1 and 2 weeks after
discontinuation of cinacalcet (in addition to the 3-week
discontinuation previously reported) and to control against
the expression of p21 in uremic rats treated with vehicle
for 9 weeks and in normal, sham-operated rats treated
with cinacalcet or vehicle. Expression of p21 in parathyroid
gland sections (p21-positive cells/mm
2) from uremic rats
1 week after discontinuation of cinacalcet was ~2.5-fold
higher than in 5/6 Nx rats treated with vehicle at the end
of 6 weeks of treatment (Figure 5;P< 0.05), similar to the
~2.5-fold increase at the end of 6 weeks of cinacalcet pre-
viously reported by Drueke et al. [1]. There was a trend for
expression of p21 to be elevated 2 weeks after discontinu-
ation of cinacalcet (Figure 5); however, the overall effect
was not signiﬁcant. The expression of p21 in uremic rats
treated with vehicle for 9 weeks was not signiﬁcantly dif-
ferent from rats treated with vehicle for 6 weeks or in rats 3
weeks after discontinuation of cinacalcet (Figure 5). Cina-
calcet had no effect on the number of p21-positive para-
thyroid cells in control sham-operated rats compared with
sham-operated vehicle-treated rats (Figure 5).
Cinacalcet effects on serum BUN, creatinine, calcium and
phosphorous. Uremic induction following 5/6 Nx in rats
resulted in a signiﬁcant (P < 0.05) elevation in BUN and
creatinine indicative of CKD (Table 1). Treatment (cina-
calcet or vehicle) had no effect on these biomarkers of
uremia in either sham or 5/6 Nx rats (Table 1).
Cinacalcet signiﬁcantly decreased serum calcium
(Figure 6) and increased serum phosphorous (Figure 7)
in 5/6 Nx rats treated daily for 6 weeks compared with
vehicle-treated 5/6 Nx animals. This effect did not persist
after discontinuation of cinacalcet treatment; serum calcium
and phosphorous returned toward vehicle-treated control lev-
els by Weeks 7, 8 and 9 corresponding to 1, 2 and 3 weeks,
respectively, after treatment termination (Figures 6 and 7).
This is in contrast to the persisting effect in 5/6 Nx rats treated
continuously with cinacalcet for the whole 9-week period
(Figures 6 and 7). In sham-operated rats, 9-week cinacalcet
treatment signiﬁcantly decreased serum calcium and in-
creased serum phosphorous compared with sham animals
treated with vehicle for the same duration (Figures 6 and 7).
Experiment 2—therapeutic cinacalcet regimen:
reduction of parathyroid gland hyperplasia in response
to therapeutic administration of cinacalcet in rats with
established CKD
Cinacalcet reverses established PTH elevations and
parathyroid hyperplasia. Serum PTH (pg/mL) measured
6 weeks after 5/6 Nx and before treatment with cinacalcet
(329   51; n ¼ 10) or vehicle (298   50; n ¼ 10) was
signiﬁcantly higher (P < 0.05) than PTH in sham-operated
rats (115   13; n ¼ 10) (Figure 1B). Administration of
cinacalcet to 5/6 Nx animals for 5 weeks starting 6 weeks
after surgery resulted in signiﬁcantly reduced serum PTH
(25   5 pg/mL, n ¼ 9; P < 0.001) compared to 5/6 Nx rats
treated with vehicle (398   81 pg/mL) or sham-operated
rats treated with vehicle (162   27 pg/mL; P < 0.05) for
the same period.
Fig. 4. Continued cinacalcet treatment is required to prevent increases in
parathyroid glandular weight. Parathyroid tissue weights from cinacalcet-
or vehicle-treated rats at the end of 6 or 9 weeks of treatment and 1–3
weeks after termination of treatment. 5/6 Nx and sham rats were treated
with cinacalcet (10 mg/kg/day) or vehicle for 6 weeks followed by up to 3
weeks of vehicle in all groups. Rats were sacriﬁced at 6, 7, 8 or 9 weeks,
and parathyroid weights were determined. Data represent mean 6 SEM
(*P < 0.05 as compared to 5/6 Nx, vehicle, sacriﬁce 6 week; #P < 0.05 as
compared to 5/6 Nx, vehicle, sacriﬁce 9 week; n ¼ 13–17 parathyroid
glands per group).
Fig. 5. Continued cinacalcet treatment is required to maintain increases in
p21 expression in parathyroid glands. Number of p21-positive cells from
cinacalcet- or vehicle-treated rats at the end of 6 or 9 weeks of treatment
and 1–3 weeks after termination of treatment. 5/6 Nx and sham rats were
treated with cinacalcet (10 mg/kg/day) or vehicle for 6 weeks followed by
up to 3 weeks of vehicle in all groups. Rats were sacriﬁced at 6, 7, 8 or 9
weeks, and numbers of p21-positive cells were determined. Data represent
mean 6 SEM (*P < 0.05 as compared to 5/6 Nx, vehicle, sacriﬁce 6 week;
adata previously reported [1]; n ¼ 13–17 parathyroid gland sections
stained for p21 per group).
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weeks starting 6 weeks after surgery resulted in signiﬁ-
cantly reduced parathyroid hyperplasia (41   8 PCNA-
positive cells/mm
2 and 0.396   0.031 mg parathyroid
gland weight) as compared to 5/6 Nx rats treated with
vehicle [83   8 PCNA-positive cells/mm
2 (P < 0.001)
and 0.566   0.038 mg parathyroid gland weight (P <
0.05)]. Parathyroid hyperplasia in vehicle-treated 5/6 Nx
rats (11 weeks post-5/6 Nx) was not increased over that
of a separate group of vehicle-treated 5/6 Nx rats sacriﬁced
6 weeks after surgery (78   9 PCNA-positive cells/mm
2
and 0.607   0.045 mg parathyroid gland weight) but was
signiﬁcantly increased compared to vehicle-treated sham
rats [27   5 PCNA-positive cells/mm
2 (P < 0.001) and
0.362   0.030 mg parathyroid gland weight (P < 0.05)],
indicating signiﬁcant parathyroid hyperplasia in the uremic
animals at 6 and 11 weeks after surgery.
Cinacalcet effects on serum BUN, creatinine, calcium and
phosphorous. Serum markers of uremia including BUN
Table 1. Effect of preventative cinacalcet treatment on BUN and creatinine levels in CKD rats (Experiment 1)
a
Experiment 1
5/6 Nx Sham
Vehicle Cinacalcet Vehicle Cinacalcet
BUN (mg/dL)
Baseline (prior to surgery) 23 6 12 1 6 02 2 6 12 2 6 1
6 week (6 weeks of treatment) 52 6 3* 58 6 9* 22 6 12 1 6 1
Baseline (prior to surgery) 21 6 12 1 6 12 2 6 12 2 6 1
9 week (9 weeks of treatment) 61 6 15* 42 6 2* 22 6 11 9 6 1
Creatinine (mmol/L)
Baseline (prior to surgery) 0.4 6 0.0 0.3 6 0.0 0.4 6 0.0 0.4 6 0.0
6 week (6 weeks of treatment) 0.9 6 0.0* 1.1 6 0.2* 0.4 6 0.0 0.4 6 0.0
Baseline (prior to surgery) 0.4 6 0.0 0.4 6 0.0 0.4 6 0.0 0.4 6 0.0
9 week (9 weeks of treatment) 1.2 6 0.3* 0.8 6 0.0* 0.4 6 0.0 0.4 6 0.0
aValues are mean 6 SEM from serum collected 4 h after last treatment, n ¼ 8–10 animals per group. In 5/6 Nx animals, values were measured from the
same group of animals at baseline and 6 weeks or a different group of animals at baseline and 9 weeks. In sham animals, values were measured from the
same group of animals at baseline, 6 weeks and 9 weeks.
*P < 0.05 versus sham-vehicle or sham-cinacalcet (10 mg/kg).
Fig. 6. Total serum calcium in cinacalcet- or vehicle-treated rats at the end
of 6 or 9 weeks of treatment and 1–3 weeks after termination of treatment.
5/6 Nx and sham rats were treated with cinacalcet (10 mg/kg/day) or
vehicle for 6 weeks followed by up to 3 weeks of vehicle in all groups.
Values(mean6SEM;n¼8–10pergroup)shownarefrombloodsamples
collected 4 h post-treatment at the end of 6, 7, 8 or 9 weeks after 5/6 Nx or
sham surgery. Data represent mean 6 SEM (*P < 0.05 as compared to 5/6
Nx, vehicle, sacriﬁce 6 week; #P < 0.05 as compared to 5/6 Nx, vehicle,
sacriﬁce 9 week; ^P < 0.05 as compared to sham, vehicle, sacriﬁce 9
week; n ¼ 8–10 per group).
Fig. 7. Total serum phosphorus in cinacalcet- or vehicle-treated rats at the
end of 6 or 9 weeks of treatment and 1–3 weeks after termination of
treatment. 5/6 Nx and sham rats were treated with cinacalcet (10 mg/kg/
day) or vehicle for 6 weeks followed by up to 3 weeks of vehicle in all
groups. Values (mean 6 SEM; n ¼ 8–10 per group) shown are from blood
samples collected 4 h post-treatment at the end of 6, 7, 8 or 9 weeks after
5/6 Nx or sham surgery. Data represent mean 6 SEM (*P < 0.05 as
compared to 5/6 Nx, vehicle, sacriﬁce 6 week; n ¼ 8–10 per group).
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treated with vehicle for 5 weeks starting 6 weeks after
surgery (11 weeks total post-5/6 Nx) compared to baseline
pre-surgical levels (Table 2;P< 0.01) or vehicle-treated
sham rats (Table 2;P< 0.01), indicating persistence of
CKD. There was no signiﬁcant effect of cinacalcet treat-
ment in 5/6 Nx rats on these serum markers of uremia
(Table 2).
Cinacalcet treatment of 5/6 Nx animals for 5 weeks start-
ing 6 weeks after surgery (11 weeks post-5/6 Nx) resulted
in signiﬁcantly decreased serum calcium and increased se-
rum phosphorous compared to vehicle-treated 5/6 Nx ani-
mals at the end of 5 weeks of treatment (Table 2). Serum
calcium and phosphorous levels in vehicle-treated 5/6 Nx
animals were not signiﬁcantly different than vehicle-treated
sham animals (Table 2).
Discussion
These studies demonstrate that prophylactic treatment with
cinacalcet, an allosteric modulator of the CaSR, reduced
parathyroid cell proliferation and PTH in rats with sHPT,
consistent with previous preventative studies utilizing cal-
cimimetics [23–25]. Additionally, we demonstrated that
discontinuation of calcimimetic treatment released the in-
hibition of parathyroid proliferation resulting in the devel-
opment of parathyroid hyperplasia and return of PTH to
levels observed in vehicle-treated rats. More importantly,
we also demonstrated for the ﬁrst time that a therapeutic
paradigm of cinacalcet administration in rats with estab-
lished uremia and sHPT can mediate regression of para-
thyroid cell proliferation and prevent increases in
parathyroid gland weight. In addition to attenuating estab-
lished parathyroid hyperplasia, cinacalcet caused a rapid
decrease in serum PTH and calcium in 5/6 Nx rats and is
in agreement with previous observations in normal and
uremic rats and CKD patients on dialysis [20, 22, 23].
The present data, coupled with previous ﬁndings with an-
other calcimimetic, R-568, offer encouraging support for
efﬁcient targeting of the CaSR with cinacalcet in sHPT.
The studies described herein show that parathyroid cell
proliferation was reduced to control levels by cinacalcet
treatment using either a prophylactic or therapeutic dosing
regimen. These ﬁndings are in agreement with preventative
studies with cinacalcet or the calcimimetic R-568 that
showed inhibition of parathyroid cell proliferation in the
5/6 Nx rats [23, 24]. Furthermore, these data serve to sup-
port clinical ﬁndings demonstrating reduced parathyroid
glandular volume and regression of parathyroid gland swel-
ling in patients treated with cinacalcet as visualized by
ultrasound [26, 27, 29]. This cinacalcet-induced reduction
in parathyroid gland volume has subsequently been shown
to be associated with decreased serum PTH [29]. It is im-
portant to note that the experimental model of sHPT that
was used in the present studies, namely the 5/6 Nx, has
limitations in that renal failure is not as extensive as it is in
end-stage renal disease (ESRD) patients. This is exempli-
ﬁed by the differences in calcimimetic effects on serum
phosphorous. Cinacalcet lowers serum phosphorous in
ESRD patients; however, in the 5/6 Nx model, serum phos-
phorous is elevated. The effects on serum phosphorus ob-
served in this study are to be expected in the presence of a
partially functioning kidney (1/6th kidney function remain-
ing) based on the known physiological effect of PTH on
urinary phosphorous excretion and is consistent with the
phosphatemic effect of cinacalcet observed in a phase II
trial in patients with CKD not on dialysis (Stage 3/4) [32].
However, this is in stark contrast to the phosphate lowering
effect in dialysis patients with very little no residual kidney
function (CKD Stage 5) for whom cinacalcet is indicated
[22]. Cinacalcet effects on PTH and calcium observed are
in agreement with effects in patients.
Parathyroid hyperplasia involves a complex cascade of
events, in which decreases in circulating calcium and 1,25-
dihydroxyvitamin D and retention of phosphate have been
implicated in disease progression; thus, decreased signaling
through the CaSR is thought to be a major pathway pro-
moting the progression of parathyroid hyperplasia. This
hypothesis is supported by the fact that parathyroid hyper-
plasia is found in neonatal severe hyperparathyroidism, a
disease attributed to loss-of-function mutations in the CaSR
Table 2. Effect of therapeutic cinacalcet treatment on BUN, creatinine, calcium and phosphorous levels in CKD rats (Experiment 2)
a
Experiment 2
5/6 Nx
Sham
Vehicle Cinacalcet Vehicle
BUN (mg/dL)
Baseline (prior to surgery) 18 6 11 9 6 11 9 6 1
11 week (6 weeks vehicle 1 5 weeks of treatment) 54 6 4** 48 6 7** 21 6 1
Creatinine (mmol/L)
Baseline (prior to surgery) 0.3 6 0.0 0.4 6 0.0 0.3 6 0.0
11 week (6 weeks vehicle 1 5 weeks of treatment) 1.1 6 0.2** 0.8 6 0.1** 0.4 6 0.0
Calcium (mg/dL)
11 week (6 weeks vehicle 1 5 weeks of treatment) 11.4 6 0.3 10.1 6 0.2* 11.2 6 0.3
Phosphorous (mg/dL)
11 week (6 weeks vehicle 1 5 weeks of treatment) 6.4 6 0.4 8.0 6 0.4* 5.9 6 0.3
aValues are mean 6 SEM, n ¼ 10 animals per group.
*P < 0.05 versus vehicle-treated 5/6 Nx.
**P < 0.01 versus sham-vehicle.
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roid gland hyperplasia, suggesting that CaSR regulates
chief cell proliferation in the absence of uremia [34].
The principal regulator of PTH secretion is serum cal-
cium, which acts on CaSR in the parathyroid gland and has
previously been shown to decrease parathyroid hyperplasia
[35]. In the CKD setting, there is a reduced CaSR expres-
sion as parathyroid glands enlarge and undergo hyperplasia
[36, 37]. The consequences of CaSR reductions could lead
to abnormal calcium-regulated PTH secretion. Downregu-
lation of CaSR is associated with high proliferative activity
of parathyroid glands in patients with sHPT [38] and in
uremic rats [39]. The reduction in CaSR and VDR, and
enlargement of the parathyroid glands that causes enhanced
capacity for PTH production, might explain why parathy-
roid glands become increasingly resistant to regulation by
calcium and 1,25-dihydroxyvitamin D. Clinically, patients
treated with cinacalcet have been shown to exhibit reduced
parathyroid glandular volume [26] and regression of para-
thyroid gland swelling [27]. The efﬁcacy of cinacalcet in
reduction of gland volume in the Meola et al. [26] study
appeared to be dependent upon the baseline gland volume
(<500 mm
3) supporting the notion that if disease progres-
sion is too advanced, the parathyroids may become increas-
ingly resistant to therapy. However, in a 52-week,
multicenter open-label study of patients receiving hemo-
dialysis with moderate to severe sHPT, cinacalcet de-
creased serum PTH and reduced parathyroid gland
volume in patients with marked parathyroid hyperplasia
(i.e. regardless of baseline parathyroid size) [29].
A potential mechanism underlying the ability of calcimi-
metics to prevent parathyroid cell proliferation in uremic
rats is through increased expression of the cell cycle inhib-
itor p21 [1, 30], which controls cell entry into the actively
dividing S phase through inhibition of the activity of a
number of CDKs [40]. In the present study, cinacalcet ob-
viated the effects of uremia on parathyroid cell proliferation
after 6 weeks of treatment and at this time, p21 expression
was reportedly increased [1]. Interestingly, 1 week after
discontinuation of cinacalcet, p21 expression remained sig-
niﬁcantly elevated (Figure 5) and the number of proliferat-
ing cells (PCNA-positive cells) in the parathyroid gland
was still signiﬁcantly decreased (Figure 3). Thus, cinacal-
cet-mediated increases in p21 expression in the parathyroid
glands from uremic rats may keep cells under normal cell
cycle control and prevent them from entering a proliferative
hyperplastic state. While the underlying mechanism of cal-
cimimetic-induced increases in p21 in uremic rats has not
been completely elucidated, the observation that calcimi-
metics increase this endogenous inhibitor of cell cycle CDK
activity may explain why parathyroid cell proliferation
is decreased in calcimimetic-treated compared to vehicle-
treated rats. However, it is also possible that instead of being
causative, changes in p21 may be a response to the changes
in cell proliferation. It is noteworthy that 3 weeks following
discontinuation of cinacalcet, p21 was no longer increased
in uremic rats and parathyroid cell proliferation, parathy-
roid gland weights and PTH were increased to levels ob-
served in vehicle-treated uremic rats. This reversibility of
the effects of cinacalcet is in contrast to parathyroidectomy
as an alternative therapeutic option for parathyroid hyper-
plasia, which by nature has irreversible effects. Each treat-
ment has beneﬁts and drawbacks that need to be weighed
by the physician and patient to determine the proper clinical
decision. Reversibility of cinacalcet effects on parathyroid
gland proliferation after discontinuation of treatment sug-
gests that treatment with cinacalcet must be maintained in
order to keep parathyroid hyperplasia suppressed. Whether
CaSR signaling directly regulates p21 expression remains
to be determined.
In contrast to the increased p21expression and decreased
parathyroid hyperplasia in cinacalcet-treated uremic rats,
parathyroid hyperplasia and p21 expression were unaf-
fected in vehicle-treated uremic rats and expression re-
mained at low levels in these animals. This ﬁnding
conﬁrms those previously reported indicating that p21 does
not increase in uremic rats or humans with diffuse hyper-
plasia [7]. However, when disease progresses (e.g. severe
nodular parathyroids), expression of p21 has been reported
to decrease, suggesting that loss of p21 may lead to cell
cycle deregulation and promote disease progression to a
more severe state [7]. Factor(s) that prevent upregulation
of p21 in uremic animals to keep parathyroid cells from
entering the proliferative state or that downregulate p21 in
severe disease states have not been identiﬁed.
Taken together, these ﬁndings demonstrate that the ef-
fects of cinacalcet are not limited to decreasing serum PTH
levels but extend to modifying disease progression by re-
ducing parathyroid cell proliferation and gland weight in
CKD animals. While these ﬁndings in an animal model of
CKD are not directly applicable to parathyroid hyperplasia
in CKD patients, recent clinical ﬁndings demonstrating that
cinacalcet appears to attenuate progression of parathyroid
hyperplasia supports the notion that cinacalcet could arrest
the development of parathyroid hyperplasia in CKD pa-
tients. However, further research with reﬁned imaging ca-
pabilities in larger patient populations is warranted to
determine at what stage of hyperplasia and gland size can
therapeutic intervention be effective, and if cinacalcet can
reverse parathyroid hyperplasia in CKD patients, as ob-
served in this animal model of CKD. The present preclin-
ical data demonstrating that discontinuation of cinacalcet
results in loss of PTH control and return of parathyroid
hyperplasia suggests that continued therapy is likely war-
ranted to keep the disease under control in patients.
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